Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net revenue:
Total net revenue		$ 101,132	$ 118,060	$ 312,262	$ 329,313
Cost of revenue:
Total cost of revenue	[1]	72,058	79,342	207,793	213,031
Gross profit		29,074	38,718	104,469	116,282
Operating expenses:
Research and development	[2]	10,909	14,209	40,203	42,942
Selling and marketing		10,318	11,130	31,923	35,511
General and administrative		12,409	11,063	38,656	34,990
Total operating expenses		33,636	36,402	110,782	113,443
Income (loss) from operations		(4,562)	2,316	(6,313)	2,839
Income from equity method investment, net		1,024	2,027	1,028	960
Other expense, net		(2,360)	(3,222)	(10,393)	(8,611)
Income (loss) before provision for income taxes		(5,898)	1,121	(15,678)	(4,812)
Provision for income taxes		444	522	3,254	1,912
Net income (loss)		$ (6,342)	$ 599	$ (18,932)	$ (6,724)
Net income (loss) per share - basic		$ (0.06)	$ 0.01	$ (0.19)	$ (0.07)
Net income (loss) per share - diluted		$ (0.06)	$ 0.01	$ (0.19)	$ (0.07)
Weighted average common shares used in computing net income (loss) per share:
Basic		99,197	95,522	97,838	94,532
Diluted		99,197	97,455	97,838	94,532
Other comprehensive income (loss):
Net Income (Loss)		$ (6,342)	$ 599	$ (18,932)	$ (6,724)
Foreign currency translation adjustment		(2,965)	801	(2,330)	(64)
Comprehensive income (loss)		(9,307)	1,400	(21,262)	(6,788)
Products
Net revenue:
Total net revenue	[3]	49,603	62,846	154,491	170,738
Cost of revenue:
Total cost of revenue		35,945	43,529	105,977	111,627
Services
Net revenue:
Total net revenue	[4]	51,529	55,214	157,771	158,575
Cost of revenue:
Total cost of revenue		$ 36,113	$ 35,813	$ 101,816	$ 101,404

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $13,887 and $40,260 during the three and nine months ended March 31, 2024 and $13,905 and $29,728 during the three and nine months ended March 31, 2023, respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $199 during the nine months ended March 31, 2024, and $97 and $1,363 during the three and nine months ended March 31, 2023, respectively. There were no charge backs to the joint venture related to research and development during the three months ended March 31, 2024.

[3] Includes sales of products to the joint venture, an equity method investment, of $15,662 and $55,504 during the three and nine months ended March 31, 2024 and $18,118 and $43,702 during the three and nine months ended March 31, 2023, respectively. See Note 13.

[4] Includes sales of services to the joint venture, an equity method investment, of $3,982 and $10,970 during the three and nine months ended March 31, 2024 and $2,696 and $8,147 during the three and nine months ended March 31, 2023, respectively. See Note 13.